Valuation: Avadel Pharmaceuticals plc

Market Cap 2.12B 1.86B 1.71B 1.58B 3B 203B 3.05B 20.48B 8.04B 99.8B 7.98B 7.8B 343B P/E 2024
-20.5x
P/E 2025 33.7x
Enterprise Value 2B 1.75B 1.61B 1.49B 2.82B 190B 2.87B 19.23B 7.55B 93.74B 7.49B 7.33B 322B EV / Sales 2024
5.78x
EV / Sales 2025 7.12x
Free-Float
99.5%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Avadel Pharmaceuticals plc

1 day+0.05%
6 months+0.65%
Current year+0.42%
Current year 21.4
Extreme 21.395
21.76
1 year 9.54
Extreme 9.54
23.57
3 years 6.38
Extreme 6.38
23.57
5 years 6.38
Extreme 6.38
23.57
10 years 6.38
Extreme 6.38
23.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2020-12-06
Chief Tech/Sci/R&D Officer - 2019-12-01
Investor Relations Contact - -
Date Insider Type Main position Quantity % Market Cap.
02-12
Weiss Asset Management LP
SellCompany 11,112,052 11.3600%
02-11Issuer sale

Chief Operating Officer

300,000 0.3067%
02-11Issuer sale

Director

380,025 0.3885%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%-.--%+125.18% - 2.12B
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-3.72%-1.10%+18.41%+70.56% 161B
Average -1.05%-2.92%+36.57%+56.70% 357.6B
Weighted average by Cap. -1.31%-2.96%+36.80%+83.91%

Financials

2024 2025
Net sales 169M 148M 136M 126M 239M 16.13B 243M 1.63B 640M 7.95B 635M 621M 27.32B 279M 244M 225M 208M 395M 26.62B 401M 2.69B 1.06B 13.12B 1.05B 1.03B 45.09B
Net income -48.83M -42.71M -39.4M -36.39M -69.04M -4.66B -70.21M -471M -185M -2.29B -183M -179M -7.89B 64.67M 56.57M 52.18M 48.19M 91.44M 6.17B 92.98M 623M 245M 3.04B 243M 238M 10.45B
Net Debt -34.93M -30.56M -28.18M -26.03M -49.39M -3.33B -50.22M -337M -132M -1.64B -131M -128M -5.64B -129M -113M -104M -96.05M -182M -12.29B -185M -1.24B -488M -6.06B -484M -473M -20.82B
Logo Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Employees
188
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. AVDL Stock